Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis.

apoptosis cancer evasion extrinsic intrinsic sesquiterpene lactones

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 15 01 2024
accepted: 26 02 2024
medline: 26 3 2024
pubmed: 26 3 2024
entrez: 26 3 2024
Statut: epublish

Résumé

Apoptosis is a programmed cell death comprising two signaling cascades including the intrinsic and extrinsic pathways. This process has been shown to be involved in the therapy response of different cancer types, making it an effective target for treating cancer. Cancer has been considered a challenging issue in global health. Cancer cells possess six biological characteristics during their developmental process known as cancer hallmarks. Hallmarks of cancer include continuous growth signals, unlimited proliferation, resistance to proliferation inhibitors, apoptosis escaping, active angiogenesis, and metastasis. Sesquiterpene lactones are one of the large and diverse groups of planet-derived phytochemicals that can be used as sources for a variety of drugs. Some sesquiterpene lactones possess many biological activities such as anti-inflammatory, anti-viral, anti-microbial, anti-malarial, anticancer, anti-diabetic, and analgesic. This review article briefly overviews the intrinsic and extrinsic pathways of apoptosis and the interactions between the modulators of both pathways. Also, the present review summarizes the potential effects of sesquiterpene lactones on different modulators of the intrinsic and extrinsic pathways of apoptosis in a variety of cancer cell lines and animal models. The main purpose of the present review is to give a clear picture of the current knowledge about the pro-apoptotic effects of sesquiterpene lactones on various cancers to provide future direction in cancer therapeutics.

Identifiants

pubmed: 38529189
doi: 10.3389/fphar.2024.1371002
pii: 1371002
pmc: PMC10961375
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1371002

Informations de copyright

Copyright © 2024 Hsu, Rajabi, Hamzeloo-Moghadam, Kumar, Maresca and Ghildiyal.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Chou-Yi Hsu (CY)

Department of Pharmacy, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.

Sadegh Rajabi (S)

Traditional Medicine and Materia Medica Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Maryam Hamzeloo-Moghadam (M)

Traditional Medicine and Materia Medica Research Center and Department of Traditional Pharmacy, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abhinav Kumar (A)

Department of Nuclear and Renewable Energy, Ural Federal University Named After the First President of Russia Boris Yeltsin, Ekaterinburg, Russia.

Marc Maresca (M)

Aix Marseille Univ, CNRS, Centrale Marseille, iSm2, Marseille, France.

Pallavi Ghildiyal (P)

Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India.

Classifications MeSH